NATURAL-HISTORY OF CLINICALLY LOCALIZED PROSTATE-CANCER

被引:8
|
作者
BARRY, MJ
机构
[1] Medical Practices Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
来源
SEMINARS IN SURGICAL ONCOLOGY | 1995年 / 11卷 / 01期
关键词
PROSTATIC NEOPLASMS; PROGNOSIS; MORTALITY; RISK FACTORS; EPIDEMIOLOGY;
D O I
10.1002/ssu.2980110103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The natural history of clinically localized prostate cancer is controversial. However, the data that is available suggests outcomes are good for men with well and moderately differentiated disease, but relatively poor for men with poorly differentiated cancer. For example, in one synthesis of individual-patient level data from six series, ten-year prostate cancer-specific mortality for men with well, moderate, and poorly differentiated disease was estimated at 13%, 13%, and 66%, respectively. Tumor grade is the dominant predictor of prognosis. Few studies report on risks of morbidity due to local cancer progression; the data available suggest this risk is relatively low. Cancer-specific mortality figures overestimate the impact of disease among older men with competing causes of mortality. Given the available data on prognosis of men with localized prostate cancer not treated for cure, clinical trials designed to measure the effectiveness of aggressive therapy will need to be large. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 50 条
  • [31] RECENT RESULTS OF MANAGEMENT OF PALPABLE CLINICALLY LOCALIZED PROSTATE-CANCER - REPLY
    ADOLFSSON, J
    STEINECK, G
    WHITMORE, WF
    CANCER, 1994, 73 (07) : 2007 - 2008
  • [32] USE OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IN CLINICALLY LOCALIZED PROSTATE-CANCER
    FAIR, WR
    APRIKIAN, AG
    COHEN, D
    SOGANI, P
    REUTER, V
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1993, 16 (06): : 516 - 522
  • [33] PROSTATE-SPECIFIC ANTIGEN AND RADIATION-THERAPY FOR CLINICALLY LOCALIZED PROSTATE-CANCER
    ZAGARS, GK
    POLLACK, A
    KAVADI, VS
    VONESCHENBACH, AC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (02): : 293 - 306
  • [34] MANAGEMENT OF LOCALIZED PROSTATE-CANCER
    CHODAK, GW
    BIOMEDICINE & PHARMACOTHERAPY, 1994, 48 (8-9) : 408 - 408
  • [35] MANAGEMENT OF LOCALIZED PROSTATE-CANCER
    BAGSHAW, MA
    HOSPITAL PRACTICE, 1986, 21 (12): : 73 - &
  • [36] MANAGEMENT OF LOCALIZED PROSTATE-CANCER
    SMITH, JA
    CANCER, 1992, 70 (01) : 302 - 306
  • [37] HISTOPATHOLOGY OF LOCALIZED PROSTATE-CANCER
    MURPHY, GP
    BUSCH, C
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, : 7 - 40
  • [38] RADIOTHERAPY AND ANDROGEN ABLATION FOR CLINICALLY LOCALIZED HIGH-RISK PROSTATE-CANCER
    POLLACK, A
    ZAGARS, GK
    KOPPLIN, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (01): : 13 - 20
  • [39] ECHOGRAMS OF PROSTATE-CANCER - INSIDE ECHO PATTERNS OF LOCALIZED PROSTATE-CANCER
    HASEGAWA, Y
    KUMAZAWA, J
    EUROPEAN UROLOGY, 1988, 14 (01) : 9 - 14
  • [40] A DECISION-ANALYSIS OF ALTERNATIVE TREATMENT STRATEGIES FOR CLINICALLY LOCALIZED PROSTATE-CANCER
    FLEMING, C
    WASSON, JH
    ALBERTSEN, PC
    BARRY, MJ
    WENNBERG, JE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (20): : 2650 - 2658